Effets vasculaires et rénaux des médicaments anti-angiogéniques : recommandations françaises pour la pratique (SN, SFHTA, APNET, FFCD)

Miles, 2008, Management of toxicity in patients receiving therapy with bevacizumab, Eur J Cancer, 29, 10.1016/S1359-6349(08)70290-8 Risau, 1997, Mechanisms of angiogenesis, Nature, 386, 671, 10.1038/386671a0 Ferrara, 2004, Vascular endothelial growth factor: basic science and clinical progress, Endocrine Rev, 4, 581, 10.1210/er.2003-0027 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Motzer, 2007, Sunitinib versus interferon alpha in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Llovet, 2007, Sorafenib improves survival in advanced hepatocellular carcinoma, J Clin Oncol, 25, LBA1, 10.1200/jco.2007.25.18_suppl.lba1 Sandler, 2006, Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113 Rini, 2007, Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma, Clin Cancer Res, 13, 741s, 10.1158/1078-0432.CCR-06-2110 Remontet, 2003, Cancer incidence and mortality in France over the period 1978–2000, Rev Epidemiol Sante Publique, 51, 3 Hicklin, 2005, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J Clin Oncol, 23, 1011, 10.1200/JCO.2005.06.081 Ferrara, 2003, The biology of VEGF and its receptors, Nat Med, 9, 669, 10.1038/nm0603-669 Fukumura, 1998, Tumor induction of VEGF promoter activity in stromal cells, Cell, 94, 715, 10.1016/S0092-8674(00)81731-6 Houck, 1991, The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA, Mol Endocrinol, 5, 1806, 10.1210/mend-5-12-1806 Tischer, 1991, The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing, J Biol Chem, 266, 11947, 10.1016/S0021-9258(18)99049-6 Keyt, 1996, The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency, J Biol Chem., 271, 88 Le Tourneau, 2008, New developments in multitargeted therapy for patients with solid tumours, Cancer Treat Rev, 34, 37, 10.1016/j.ctrv.2007.09.003 Presta, 1997, Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res, 57, 4593 Muller, 1998, VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface, Structure, 6, 1153, 10.1016/S0969-2126(98)00116-6 Gerber, 2005, Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies, Cancer Res, 65, 671, 10.1158/0008-5472.671.65.3 Saltz, 2008, Bevacizumab in combination with Oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer, J Clin Oncol, 26, 2013, 10.1200/JCO.2007.14.9930 Giantonio, 2007, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer, J Clin Oncol, 25, 1539, 10.1200/JCO.2006.09.6305 Schmiegel, 2007, Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC), J Clin Oncol, 25, 4034a, 10.1200/jco.2007.25.18_suppl.4034 Demetri, 2006, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, Lancet, 368, 1329, 10.1016/S0140-6736(06)69446-4 George, 2007, Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers, Proc Am Soc Clin Oncol, 25, 243s http://ctep.cancer.gov/reporting/ctc.html (site consulté le 8 septembre 2008). Azizi, 2008, Home blood-pressure monitoring in patients receiving sunitinib, N Engl J Med, 358, 95, 10.1056/NEJMc072330 Glusker, 2006, Reversible posterior leukoencephalopathy syndrome and bevacizumab, N Engl J Med, 354, 980, 10.1056/NEJMc052954 Henry, 2003, The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis, Circulation, 107, 1359, 10.1161/01.CIR.0000061911.47710.8A Mourad, 2008, Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation, Ann Oncol, 19, 927, 10.1093/annonc/mdm550 Veronese, 2006, Mechanisms of hypertension associated with BAY 43-9006, J Clin Oncol, 24, 1363, 10.1200/JCO.2005.02.0503 Zhu, 2007, Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis, Am J Kidney Dis, 49, 186, 10.1053/j.ajkd.2006.11.039 Johnson, 2004, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 22, 2184, 10.1200/JCO.2004.11.022 George, 2007, Nephrotic syndrome after bevacizumab: case report and literature review, Am J Kidney Dis, 49, e23, 10.1053/j.ajkd.2006.11.024 Izzedine, 2007, Interstitial nephritis in a patient taking sorafenib, Nephrol Dial Transplant, 22, 241, 10.1093/ndt/gfm199 Eremina, 2008, VEGF inhibition and renal thrombotic microangiopathy, N Engl J Med, 358, 1129, 10.1056/NEJMoa0707330 Frangié, 2007, Renal thrombotic microangiopathy caused by anti-VEGFantibody treatment for metastatic renal-cell carcinoma, Lancet Oncol, 8, 177, 10.1016/S1470-2045(07)70037-2 Izzedine, 2007, Thrombotic microangiopathy and anti-VEGF agents, Nephrol Dial Transplant, 22, 1481, 10.1093/ndt/gfl565 Ayllon J, Janus N, Launay-Vacher V, et al. Anti-VEGF therapies, cancer and renal function. J Clin Oncol 26: 2008 suppl; abstr 16001. Sugimoto, 2003, Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria, J Biol Chem, 278, 12605, 10.1074/jbc.C300012200 Maynard, 2003, Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia, J Clin Invest, 111, 649, 10.1172/JCI17189 Strevel, 2007, Molecularly targeted oncology therapeutics and prolongation of the QT interval, J Clin Oncol, 25, 3362, 10.1200/JCO.2006.09.6925 Chu, 2007, Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib, Lancet, 370, 2011, 10.1016/S0140-6736(07)61865-0 http://www.has-sante.fr/portail/display.jsp?id=c_272459 (site consulté le 8 septembre 2008). http://afssaps.sante.fr/htm/5/liste_tensio_1.htm (site consulté le 8 septembre 2008). Levey, 1999, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation, Ann Intern Med, 130, 461, 10.7326/0003-4819-130-6-199903160-00002 Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580 Mancia, 2007, ESH-ESC practice guidelines for the management of arterial hypertension, J Hypertens, 25, 1751, 10.1097/HJH.0b013e3282f0580f Wolter, 2007, Sunitinib and hypothyroidism, N Engl J Med, 356, 1580, 10.1056/NEJMc070327 Rixe, 2007, Hypertension as a predictive factor of Sunitinib activity, Ann Oncol, 18, 1117, 10.1093/annonc/mdm184 van Heeckeren, 2007, Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?, J Clin Oncol, 25, 2993, 10.1200/JCO.2007.11.5113 Yang, 2003, A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med, 349, 427, 10.1056/NEJMoa021491 Dincer, 2006, Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension, Ann Pharmacother, 40, 2278, 10.1345/aph.1H244 Roncone, 2007, Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma, Nat Clin Pract Nephrol, 3, 287, 10.1038/ncpneph0476 Barakat, 2007, Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma, Ann Pharmacother, 41, 707, 10.1345/aph.1H635 Faivre, 2006, Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer, J Clin Oncol, 24, 25, 10.1200/JCO.2005.02.2194 Ratain, 2006, Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 2505, 10.1200/JCO.2005.03.6723 Sun, 2007, Angiogenesis inhibitors in the treatment of lung cancer, Crit Rev Oncol Hematol, 62, 93, 10.1016/j.critrevonc.2007.01.002 Rugo, 2005, Phase I trial of the oral anti-angiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results, J Clin Oncol, 23, 5474, 10.1200/JCO.2005.04.192 Wu, 2008, Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis, Lancet Oncol, 9, 117, 10.1016/S1470-2045(08)70003-2